DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

NCT02166905 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Fallopian Tube Carcinoma
Ovarian Carcinoma
Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
DRUG: Epacadostat
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Poly ICLC

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]